Immunosuppressive therapies used in IBD, such as TNF-α inhibitors and corticosteroids, may interact with AhR and GPR35 pathways either directly or indirectly through the modulation of microbiota composition. This evidence concerns the gene GPR35 and inflammatory bowel disease.